Gapping up
In reaction to strong earnings/guidance: MSO +13.1% (light volume), ZU +11.3%, ARCI +10.9%, VSI +9.6%, AREX +7.2%, (light volume), CRH +5%, MMSI +4.8% (light volume), INFI +4.4%, HVT +3.9%, TTEC +3.6% (also announces intention to acquire Sofica Group; announces increased authorization of $25 mln for share repurchases), ARIA +3.4%, PPO +3.3%, (light volume), XPO+2.9%, HD +2.7%, FTR +2.4%, VC +2.2%, FI +1.8% (light volume), NLS +1.8% (light volume), EOG +1.4% (also announced stock split), HFC +1.3% (light volume), KONG +1.2%.
Other news: DARA +41.8% (confirms KRN5500 Receives Orphan Drug Designation From FDA), IMUC +22.3% (receives orphan drug status for ICT-107 in glioblastoma in the European Union), SPNC +9.8% (achieves statistical endpoints of EXCITE ISR Adjunct Analysis ), XOMA +5.1% (confirms receipt of orphan drug designation from FDA for pyoderma gangrenosum), EGHT +4.8% (to Join S&P SmallCap 600), BCRX +3.4% (BioCryst Pharm announces peramivir NDA acceptance by the FDA), BBRY +3.3% ( introduces new products and services), NVO +3% (following yesterday's JPMorgan upgrade), KNDI +2.8% (WantChinaTimes discusses that China's promotion for new energy cars is not going well), UVE +2.7% (to Join S&P SmallCap 600), TSCO +2.1% (authorized a $1 bln increase to its existing share repurchase program, bringing the total amount authorized to date under the program to $2 bln ), YGE +1.6% (Yingli Green Energy to supply 54 MW of solar modules for seven projects in the United Kingdom), JNPR +1.5% (Board of Directors to nominate Elliot's Kevin DeNuccio and Gary Daichendt), LNKD +1% ( planning new China language service, according to reports ), KMP +0.7% (COO disclosed buying 6.6K shares at $75.50 on 2/24 worth ~$500), CIM +0.6% ( Leon Cooperman discloses 7.6% active stake in 13D filing; engaged in communications with members of the Board).
Analyst comments: TSLA +4.8% (target raised to $320 from $153 at Morgan Stanley ), BLOX +1.6% (Infoblox initiated with a Buy at Deutsche Bank)
Other news: DARA +41.8% (confirms KRN5500 Receives Orphan Drug Designation From FDA), IMUC +22.3% (receives orphan drug status for ICT-107 in glioblastoma in the European Union), SPNC +9.8% (achieves statistical endpoints of EXCITE ISR Adjunct Analysis ), XOMA +5.1% (confirms receipt of orphan drug designation from FDA for pyoderma gangrenosum), EGHT +4.8% (to Join S&P SmallCap 600), BCRX +3.4% (BioCryst Pharm announces peramivir NDA acceptance by the FDA), BBRY +3.3% ( introduces new products and services), NVO +3% (following yesterday's JPMorgan upgrade), KNDI +2.8% (WantChinaTimes discusses that China's promotion for new energy cars is not going well), UVE +2.7% (to Join S&P SmallCap 600), TSCO +2.1% (authorized a $1 bln increase to its existing share repurchase program, bringing the total amount authorized to date under the program to $2 bln ), YGE +1.6% (Yingli Green Energy to supply 54 MW of solar modules for seven projects in the United Kingdom), JNPR +1.5% (Board of Directors to nominate Elliot's Kevin DeNuccio and Gary Daichendt), LNKD +1% ( planning new China language service, according to reports ), KMP +0.7% (COO disclosed buying 6.6K shares at $75.50 on 2/24 worth ~$500), CIM +0.6% ( Leon Cooperman discloses 7.6% active stake in 13D filing; engaged in communications with members of the Board).
Analyst comments: TSLA +4.8% (target raised to $320 from $153 at Morgan Stanley ), BLOX +1.6% (Infoblox initiated with a Buy at Deutsche Bank)